Last reviewed 2026-06-02 · How we verify

Censedal (NEALBARBITAL)

Phase 2 active Small molecule

Censedal (generic name: NEALBARBITAL) is a nealbarbital drug. It is currently in Phase 2 development.

Censedal is thought to work by modulating neural activity, but its exact mechanism of action is unclear.

Censedal (NEALBARBITAL) is a small molecule drug in the nealbarbital class, but information on its development, ownership, and commercial status is limited. Its target and mechanism of action are unknown. Censedal is not FDA-approved for any indications. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to understand Censedal's clinical utility and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NEALBARBITAL
Drug class	nealbarbital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain as a busy city with many different neighborhoods. Censedal is like a traffic controller that tries to calm down the traffic, but we don't know exactly how it does this or which neighborhoods it affects. This is a simplified explanation of how Censedal might work, but more research is needed to understand its effects on the brain.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Censedal CI brief — competitive landscape report
Censedal updates RSS · CI watch RSS

Frequently asked questions about Censedal

What is Censedal?

Censedal (NEALBARBITAL) is a nealbarbital drug.

How does Censedal work?

Censedal is thought to work by modulating neural activity, but its exact mechanism of action is unclear.

What is the generic name of Censedal?

NEALBARBITAL is the generic (nonproprietary) name of Censedal.

What drug class is Censedal in?

Censedal belongs to the nealbarbital class. See all nealbarbital drugs at /class/nealbarbital.

What development phase is Censedal in?

Censedal is in Phase 2.

Drug class: All nealbarbital drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing